TGF-β And PDL-1 Inhibition in Esophageal Squamous Cell Carcinoma Combined With Chemoradiation TheRapY

This study tests a combination of two immunotherapy drugs — one that blocks a protein called TGF-β and another that blocks PD-L1 — given alongside standard chemotherapy and radiation for esophageal squamous cell cancer. The goal is to improve tumor control and survival. **You may be eligible if...** - You have been diagnosed with squamous cell carcinoma of the esophagus or the junction of the esophagus and stomach, confirmed by biopsy - Your cancer cannot be removed by surgery, or you have refused surgery - You have locally advanced disease without spread to distant organs (except possibly the neck lymph nodes) - You have had a local recurrence after prior treatment, provided it is outside the previously treated area **You may NOT be eligible if...** - Your cancer has spread widely to distant organs - You have already received prior radiation in the area that would be re-treated - You are pregnant or have significant health conditions that prevent chemotherapy or radiation Talk to your doctor to see if this trial is right for you.